332 related articles for article (PubMed ID: 21654347)
21. Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
Saito M; Iida T; Kano M
Retina; 2012 Jul; 32(7):1272-9. PubMed ID: 22547209
[TBL] [Abstract][Full Text] [Related]
22. Clinical features and follow-up results of pulsating polypoidal choroidal vasculopathy treated with photodynamic therapy.
Byeon SH; Lew YJ; Lee SC; Kwon OW
Acta Ophthalmol; 2010 Sep; 88(6):660-8. PubMed ID: 19563374
[TBL] [Abstract][Full Text] [Related]
23. Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab.
Stangos AN; Gandhi JS; Nair-Sahni J; Heimann H; Pournaras CJ; Harding SP
Am J Ophthalmol; 2010 Nov; 150(5):666-73. PubMed ID: 20719300
[TBL] [Abstract][Full Text] [Related]
24. Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability.
Koizumi H; Yamagishi T; Yamazaki T; Kinoshita S
Am J Ophthalmol; 2013 Feb; 155(2):305-313.e1. PubMed ID: 23022162
[TBL] [Abstract][Full Text] [Related]
25. Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
Sato T; Kishi S; Matsumoto H; Mukai R
Am J Ophthalmol; 2013 Jul; 156(1):95-105.e1. PubMed ID: 23628354
[TBL] [Abstract][Full Text] [Related]
26. Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
Saito M; Iida T; Kano M; Itagaki K
Graefes Arch Clin Exp Ophthalmol; 2013 Sep; 251(9):2099-110. PubMed ID: 23553286
[TBL] [Abstract][Full Text] [Related]
27. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Sato T; Kishi S; Matsumoto H; Mukai R
Am J Ophthalmol; 2010 Jun; 149(6):947-954.e1. PubMed ID: 20346441
[TBL] [Abstract][Full Text] [Related]
28. Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab.
Saito M; Kano M; Itagaki K; Oguchi Y; Sekiryu T
Retina; 2014 Nov; 34(11):2192-201. PubMed ID: 25077530
[TBL] [Abstract][Full Text] [Related]
29. Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy: changes of aqueous vascular endothelial growth factor.
Lee MY; Lee WK; Baek J; Kwon OW; Lee JH
Am J Ophthalmol; 2013 Aug; 156(2):343-8. PubMed ID: 23664208
[TBL] [Abstract][Full Text] [Related]
30. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.
Cho HJ; Baek JS; Lee DW; Cho SW; Kim CG; Kim JW
Retina; 2013; 33(10):2126-32. PubMed ID: 23609123
[TBL] [Abstract][Full Text] [Related]
31. Effects of choroidal vascular hyperpermeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.
Cho HJ; Kim HS; Jang YS; Han JI; Lew YJ; Lee TG; Kim CG; Kim JW
Am J Ophthalmol; 2013 Dec; 156(6):1192-1200.e1. PubMed ID: 24011522
[TBL] [Abstract][Full Text] [Related]
32. Two-year results of photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
Kim M; Kim K; Kim DG; Yu SY; Kwak HW
Ophthalmologica; 2011; 226(4):205-13. PubMed ID: 21893965
[TBL] [Abstract][Full Text] [Related]
33. Choroidal thickness changes after intravitreal ranibizumab and photodynamic therapy in recurrent polypoidal choroidal vasculopathy.
Maruko I; Iida T; Oyamada H; Sugano Y; Ojima A; Sekiryu T
Am J Ophthalmol; 2013 Sep; 156(3):548-556. PubMed ID: 23810474
[TBL] [Abstract][Full Text] [Related]
34. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.
Koh A; Lee WK; Chen LJ; Chen SJ; Hashad Y; Kim H; Lai TY; Pilz S; Ruamviboonsuk P; Tokaji E; Weisberger A; Lim TH
Retina; 2012 Sep; 32(8):1453-64. PubMed ID: 22426346
[TBL] [Abstract][Full Text] [Related]
35. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.
Kang HM; Koh HJ; Lee CS; Lee SC
Am J Ophthalmol; 2014 Mar; 157(3):598-606.e1. PubMed ID: 24269378
[TBL] [Abstract][Full Text] [Related]
36. Short-term effectiveness of intravitreal bevacizumab vs. ranibizumab injections for patients with polypoidal choroidal vasculopathy.
Cho HJ; Baek JS; Lee DW; Kim CG; Kim JW
Korean J Ophthalmol; 2012 Jun; 26(3):157-62. PubMed ID: 22670070
[TBL] [Abstract][Full Text] [Related]
37. Polypoidal choroidal vasculopathy in tilted disk syndrome and high myopia with staphyloma.
Mauget-Faÿsse M; Cornut PL; Quaranta El-Maftouhi M; Leys A
Am J Ophthalmol; 2006 Dec; 142(6):970-5. PubMed ID: 17046703
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal ranibizumab for polypoidal choroidal vasculopathy in non-Asian patients.
Marcus DM; Singh H; Lott MN; Singh J; Marcus MD
Retina; 2013 Jan; 33(1):35-47. PubMed ID: 22990319
[TBL] [Abstract][Full Text] [Related]
39. Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy.
Gemmy Cheung CM; Yeo I; Li X; Mathur R; Lee SY; Chan CM; Wong D; Wong TY
Am J Ophthalmol; 2013 Feb; 155(2):295-304.e1. PubMed ID: 23111181
[TBL] [Abstract][Full Text] [Related]
40. 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy.
Wong IY; Shi X; Gangwani R; Zhao P; Iu LP; Li Q; Ng A; Li X
BMC Ophthalmol; 2015 Jun; 15():66. PubMed ID: 26122636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]